Mural_Logo.jpg
Mural Oncology Presents Clinical Data from ARTISTRY-3 at the American Society of Clinical Oncology Annual Meeting
23 mai 2024 17h00 HE | Mural Oncology, Inc.
ARTISTRY-3 trial is being conducted to evaluate less frequent dosing of nemvaleukin alfa, Mural’s late-stage lead candidate Nemvaleukin demonstrated pharmacodynamic proof of mechanism in ARTISTRY-3...
Kymera-Logo-RGB-Denim+Marigold - High Res.png
Kymera Therapeutics to Present New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting
23 mai 2024 17h00 HE | Kymera Therapeutics, Inc.
Abstract released today highlights safety, pharmacodynamic and clinical response data with additional data to be presented in a poster session on June 1, 2024 KT-253 Phase 1 study ongoing with...
Nouveau Logo communiqué de presse.JPG
Theratechnologies fait une présentation sur le sudocétaxel zendusortide au Congrès 2024 de l’ASCO qui montre des signes d’une efficacité à long terme et un profil d’innocuité gérable chez les patients atteints de tumeurs solides
23 mai 2024 17h00 HE | Theratechnologies
L’affiche souligne la stabilisation durable de la maladie après la fin du traitementLes résultats suggèrent un mode d’action multimodal unique qui diffère des autres traitements contre le cancerUne...
Nouveau Logo communiqué de presse.JPG
Theratechnologies’ Sudocetaxel Zendusortide ASCO 2024 Presentation Demonstrates Signs of Long-Term Efficacy and Manageable Safety Profile in Patients with Solid Tumors
23 mai 2024 17h00 HE | Theratechnologies
Poster highlights durable disease stabilization lasting beyond treatment completionResults suggest a unique, multimodal mechanism of action that differs from other cancer therapeuticsFavorable...
IN8bioLogo.jpg
IN8bio Announces INB-200 Phase 1 Study Data in Newly Diagnosed Glioblastoma to be Presented at the 2024 ASCO Annual Meeting
23 mai 2024 17h00 HE | IN8bio, Inc
IN8bio Announces INB-200 Phase 1 Study Data in Newly Diagnosed Glioblastoma to be Presented at the 2024 ASCO Annual Meeting
ASCO24_GenericPaid_SocialBanners (3)
Physicians’ Education Resource® to host symposia at the 2024 Annual Oncology Meeting
23 mai 2024 12h47 HE | Physicians' Education Resource®
These educational activities are available to physicians, nurses, nurse practitioners, physician assistants, pharmacists and other health care professionals involved in the care of patients with...
shph logo wire.jpg
Shuttle Pharma to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024
22 mai 2024 16h15 HE | Shuttle Pharmaceuticals Holdings, Inc.
GAITHERSBURG, Md., May 22, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the...
MNW_PR
MedNews Week and OncLive® forge partnership to advance global health care education
22 mai 2024 09h00 HE | OncLive®
CRANBURY, N.J., May 22, 2024 (GLOBE NEWSWIRE) -- OncLive®, the nation’s leading multimedia resource for oncology professionals, is thrilled to announce an exciting collaboration with MedNews Week. ...
Captain T Cell Secures Seed Financing Round Totaling € 8.5 Million
22 mai 2024 04h00 HE | AKAMPION
i&i Biotech Fund I SCSp, Brandenburg Kapital GmbH and HIL-INVENT Ges.m.b.H. participated in the seed roundFunds will be used to accelerate a new generation of T cell therapies against solid tumors...
AIMLogo.jpg
AIM ImmunoTech to Participate in Two Upcoming Investor Conferences
20 mai 2024 09h15 HE | AIM ImmunoTech Inc.
OCALA, Fla., May 20, 2024 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc. (NYSE American: AIM) (“AIM” or the “Company”) today announced that AIM Chief Executive Officer Thomas K. Equels will participate in...